VacZine Analytics  
MarketVIEW: Epstein-barr virus (EBV) vaccines

Published: April 2022, September 2023 notes added

Epstein-barr virus (EBV) is a member of the herpesvirus family that exclusively infects humans, over 95% of adults worldwide harbor the virus. Primary EBV infections that occur in adolescence or early adulthood often result in infectious mononucleosis (IM), characterized by pharyngitis, cervical lymph node enlargement, fatigue and fever; complications can occur in around 1% of patients. Infectious mononucleosis is associated with an increased risk of Hodgkin lymphoma.

EBV is also associated with a variety of malignancies, including gastric carcinoma, nasopharyngeal carcinoma, Hodgkin lymphoma and Burkitt lymphoma. EBV is estimated to have caused ~1-2% of all global cancers in 2021 and is responsible for 140-200,000 deaths per year. EBV also causes Post transplant lymphoproliferative disorder (PTLD), a complication allogeneic hematologic stem cell transplants (HSCT) and to a less extent solid organ transplants (SOT). EBV is also involved with a heightened risk for multiple sclerosis [Bjornevik K et al 2022] and now possibly linked to long COVID-19.

This MarketVIEW product contains a comprehensive MS Excel-based model + Executive presentation that forecasts the potential commercial value of Epstein-barr virus (EBV) vaccines across Western economies until 2040. The model contains value ($ m) and volume (mio doses) predictions per identified vaccine target segment along with timeframe, pricing and penetration estimates for three target product profiles (TPPs) including prophylatic [PX] and therapeutic approaches [TX]. The product also includes an in depth review of latest EBV epidemiological trends, treatments/guidelines, comparative pricing assessments and latest developments in vaccinology and R&D including Moderna Therapeutics mRNA-1189, prophylatic vaccine and mRNA-1195, therapeutic vaccine, the former of which has now entered Phase I clinical development. A new NIH clinical trial for a ferritin nanoparticle adjuvanted gp350 approach has also initiated. More recent dynamics are the Merck & Co/ModeX [MDX-2201] collaboration and preclinical candidates from Valneva and EBViously.

THIS PRODUCT IS A EXECUTIVE PRESENTATION (~175 slides, .pdf + 1 MS Excel MODEL .xls) Photo credit: @austindistel

To order please contact your region account manager, buy "on-line" or order direct at: orders@vaczine-analytics.com

CAT No: CONTENTS: PURCHASE:
VAMV056 Click here>> CONTACT US
*Prices quotes are for 1 region license only. Regions are North America, or EU or ROW. For UK orders VAT will be added at 20%. On-line prices may include discounts and are converted from list price in US dollars (subject to currency fluctuations). Please review the TERMS and CONDITIONS of purchase.

Return to main list>> Questions about this report?






© 2015 VacZine Analytics. All rights reserved. Disclaimer | Privacy | Terms and conditions. hosted by chillydomains